ArticleJournal of biological engineering2026
UniSePT: an engineered broadly applicable Unique Secretory signal PepTide for high-yield biotherapeutic production in mammalian cell-based expression systems.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe yield of therapeutic proteins in mammalian cell-based production systems is often limited by inefficient secretion and reduced bioactivity caused by incompatible secretory signal peptides (SPs). Therefore, a broadly applicable signal peptide that can be fused to different proteins of interest to enhance their secretion and overall production is needed.
resultsTo address this challenge, we engineered a robust, broadly applicable Unique Secretory signal PepTide (UniSePT) by combining SP sequences from β-casein (CSN2) and β-lactoglobulin (BLG) proteins of Indian river buffalo. UniSePT demonstrated higher secretion efficiency than commonly used SPs, such as human serum albumin and preproinsulin SP. Importantly, this improved secretion does not compromise the bioactivity of the therapeutic proteins produced. Additionally, UniSePT showed minimal cleavage variability, supporting its compatibility with various therapeutic proteins.
conclusionThe newly developed UniSePT enhances the titer and bioactivity of therapeutic proteins in mammalian expression systems. Its broad applicability and improved secretion efficiency make it a promising tool for industrial-scale production, potentially reducing the cost of therapeutic protein production.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.